Showing 1 - 10 of 14
Treatment of chronic illness accounts for over 90 % of Medicare spending. Chronic lymphedema places over 3 million Americans at risk of recurrent cellulitis. Health insurers and legislators have taken an active role in fighting attempts to mandate the treatment of lymphedema for fear that...
Persistent link: https://www.econbiz.de/10011586640
Background: Treatment of chronic illness accounts for over 90% of Medicare spending. Chronic lymphedema places 3-10 million Americans at risk for recurrent cellulitis. Without convincing predictions of the costs and benefits of lymphedema treatment, insurers are reluctant to fully cover...
Persistent link: https://www.econbiz.de/10013329717
Background: Treatment of chronic illness accounts for over 90% of Medicare spending. Chronic lymphedema places 3-10 million Americans at risk for recurrent cellulitis. Without convincing predictions of the costs and benefits of lymphedema treatment, insurers are reluctant to fully cover...
Persistent link: https://www.econbiz.de/10014489844
Treatment of chronic illness accounts for over 90 % of Medicare spending. Chronic lymphedema places over 3 million Americans at risk of recurrent cellulitis. Health insurers and legislators have taken an active role in fighting attempts to mandate the treatment of lymphedema for fear that...
Persistent link: https://www.econbiz.de/10011803069
Persistent link: https://www.econbiz.de/10003704621
Persistent link: https://www.econbiz.de/10002276363
Persistent link: https://www.econbiz.de/10005329252
Persistent link: https://www.econbiz.de/10004750573
Persistent link: https://www.econbiz.de/10006744705